A possible improvement for structure-based drug design illustrated by the discovery of a Tat HIV-1 inhibitor
- 22 March 2004
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 14 (6) , 1543-1546
- https://doi.org/10.1016/j.bmcl.2003.12.095
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Discovery of a Small Molecule Tat-trans-Activation-responsive RNA Antagonist That Potently Inhibits Human Immunodeficiency Virus-1 ReplicationJournal of Biological Chemistry, 2003
- Discovery of a Tat HIV-1 Inhibitor through Computer-Aided Drug DesignJournal of Spectroscopy, 2003
- Strategies in the design of antiviral drugsNature Reviews Drug Discovery, 2002
- Approaches to solving the rigid receptor problem by identifying a minimal set of flexible residues during ligand docking11PDB coordinates have been deposited with the RSCB with accession ID: 1F28.Chemistry & Biology, 2001
- 1H-13C nuclear magnetic resonance assignment and structural characterization of HIV-1 Tat proteinComptes Rendus de l'Académie des Sciences - Series III - Sciences de la Vie, 2000
- Tat as one key to HIV-induced immune pathogenesis and Pat toxoid as an important component of a vaccineProceedings of the National Academy of Sciences, 1999
- Tetrahydropyrimidine derivatives inhibit binding of a Tat‐like, arginine‐containing peptide, to HIV TAR RNA in vitroFEBS Letters, 1995
- Inhibition of type 1 human immunodeficiency virus replication by a tat antagonist to which the virus remains sensitive after prolonged exposure in vitro.Proceedings of the National Academy of Sciences, 1993
- Inhibition of HIV Replication in Acute and Chronic Infections in Vitro by a Tat AntagonistScience, 1991
- Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patientsNature, 1990